Prevymis Contraindications

PREVYMIS is contraindicated in patients with hypersensitivity to letermovir or any of its inactive ingredients.
Pimozide: Concomitant administration of PREVYMIS may result in increased concentrations of pimozide due to inhibition of cytochrome P450 (CYP3A) by letermovir, leading to QT prolongation and torsades de pointes [see Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions under PRECAUTIONS, and Effects of PREVYMIS on Other Drugs under INTERACTIONS].
Ergot alkaloids: Concomitant administration of PREVYMIS may result in increased concentrations of ergot alkaloids (ergotamine and dihydroergotamine) due to inhibition of CYP3A by letermovir, which may lead to ergotism [see Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions under PRECAUTIONS, and Effects of PREVYMIS on Other Drugs under INTERACTIONS].
Cyclosporine with pitavastatin or simvastatin: Concomitant administration of PREVYMIS in combination with cyclosporine may result in significantly increased pitavastatin or simvastatin concentrations, which may lead to myopathy or rhabdomyolysis [see Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions under PRECAUTIONS, and Effects of PREVYMIS on Other Drugs under INTERACTIONS].